ALLPS VERSUS PVO Randomized Controlled Trial (ALPPS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer. Both treatments are types of 2-stage hepatectomies for removing liver cancer. ALPPS may be more effective than PVO in patients whose disease would traditionally be considered inoperable.
- Trial with surgical intervention
| Condition | Intervention | Phase |
|---|---|---|
|
Liver Tumors Not Resectable in One Surgical Procedure |
Procedure: Associating liver partition and portal vein ligation for staged hepatectomy Procedure: Portal vein embolization or ligation |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial |
- Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ] [ Time Frame: 2012 to 2015 ] [ Designated as safety issue: No ]
- rate of hypertrophy over time [ Time Frame: 2012 to 2015 ] [ Designated as safety issue: No ]
- Complications of treatment [ Time Frame: 2012-2015 ] [ Designated as safety issue: Yes ]
- Progression of disease [ Time Frame: 2012-2015 ] [ Designated as safety issue: No ]Progression free survival
- Postoperative liver and renal function [ Time Frame: 2012 to 2015 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 80 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | November 2015 |
| Estimated Primary Completion Date: | November 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ALPPS
Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
|
Procedure: Associating liver partition and portal vein ligation for staged hepatectomy |
|
Active Comparator: PVO
Patient undergo portal vein embolization or ligation
|
Procedure: Portal vein embolization or ligation |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria: •Patient may have primary or secondary hepatic malignancies with a FLR/TLV < 30% or a FLR/BW ratio of < 0.5 for patients with normal liver function (defined as normal transaminases, normal bilirubin, normal factor V, and normal PT/INR). In case of injury due to chemotherapy, known high grade steatosis, or cholestasis > 50 mmol/L, patient may be enrolled into the trial if FLR/TLV is < 40% or FLR/BW ratio < 0.8.
- Patient must have extensive liver tumors that would require portal vein embolization or a two-stage hepatectomy and portal vein embolization or ligation by the judgment of surgeons in the tumor board.
- Patient may have extrahepatic disease as long as it may be addressed after liver surgery and there is a tumor board decision to proceed with liver resection (mostly applicable to CRC metastases).
- Patient may have received previous chemotherapy.
- In cases of cholestasis, preoperative drainage procedures (PTC or ERCP) are left up to judgement of physicians.
- Patient must be = 18 years of age. The patient population over 65 years old needs to be carefully included based on comorbidities.
- Patient may have undergone previous liver resection.
- Patient's location must be such that proper staging and follow-up may be performed.
- Patient's case must be presented at the Multidisciplinary Meeting attended by hepatobiliary surgeons, oncologists, hepatologists, and radiologists, or must be approved directly by Dr. Strasberg or Dr. Chapman.
Exclusion criteria: •Patient must not have any significant concomitant diseases rendering him/her unsuitable for major liver surgery by the judgment of the physicians involved, especially if the patient is > 65 years old.
- Patient must not have enrolled into a clinical trial within 4 weeks of study entry.
- Patient must not have peritoneal carcinomatosis or other extensive extrahepatic disease.
- Patient must not have advanced stages of carcinoma of the gallbladder (T3/T4)
- Patient must not have issues such as drug and/or alcohol abuse.
- Patient must not need major extrahepatic surgery (e.g. pancreas resection, gastric resection, rectal surgery) within 3 months of study entry.
- Patient must not be a candidate for liver transplantation in case of HCC.
- Patient must not be pregnant or breastfeeding. If a female of childbearing potential, patient must have a negative pregnancy test within 14 days of enrollment.
Contacts and Locations| Contact: Erik Schadde, MD | +41 (0)44 255 11 11 | erik.schadde@usz.ch |
| United States, Missouri | |
| Washington University | Not yet recruiting |
| St. Louis, Missouri, United States | |
| Contact: Steven Strasberg, MD PhD strasberg@wudosis.wustl.edu | |
| Principal Investigator: Steven Strasberg, MD PhD | |
| Argentina | |
| Italian Hospital, Department of Surgery, Division of HPB surgery and Liver Transplatn Unit | Not yet recruiting |
| Buenos Aires, Argentina | |
| Contact: Victoria Ardiles, MD victoria.ardiles@hospitalitaliano.org.ar | |
| Principal Investigator: Eduardo De Santibanes, MD | |
| Switzerland | |
| University Hospital Zurich, Division of Visceral and Transplant Surgery | Recruiting |
| Zurich, ZH, Switzerland, 8091 | |
| Contact: Erik Schadde, MD erik.schadde@usz.ch | |
| Principal Investigator: Pierre-Alain Clavien, MD PhD | |
| Principal Investigator: | Erik Schadde, MD | University Hospital Zurich, Division of Visceral and Transplant Surgery |
More Information
No publications provided
| Responsible Party: | University of Zurich |
| ClinicalTrials.gov Identifier: | NCT01775267 History of Changes |
| Other Study ID Numbers: | USZ-ZH-VIS-ALPPS |
| Study First Received: | January 22, 2013 |
| Last Updated: | January 23, 2013 |
| Health Authority: | Switzerland: Swissmedic United States: Food and Drug Administration Argentina: Ministry of Health |
Additional relevant MeSH terms:
|
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Liver Diseases |
ClinicalTrials.gov processed this record on June 17, 2013